Business
Precipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 Panel
Advanced panel already generating six-figure pre-orders NEW HAVEN, Conn., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio,
About this update from Precipio, Inc.
[{"type":"text","content":"Advanced panel already generating six-figure pre-orders\nNEW HAVEN, Conn., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces the launch of its new quantitative BCR-ABL 2.0 panel, with features making it the most innovative panel of its kind on the market. For more information on this new panel please visit us at https://tinyurl.com/QBCR-ABL1. Patients with Chronic Myeloid Leukemia (CML) have cells which contain an abnormal gene, BCR-ABL1. This gene creates a hybrid protein that results in uncontrolled cell division and genomic instability1. The presence of the BCR-ABL1 oncogene confirms the diagnosis of CML; it is also used for the monitoring of patients to gauge their response to various therapies, and therefore is frequently tested in laboratories. The following features make this product the most advanced BCR-ABL panel on the market, besting competition in terms of robust coverage, workflow ease, accuracy, and cost: 1. Industry leading clinical coverage improves patient care. Precipio’s HemeScreen BCR-ABL 2.0 assay is the only panel on the market that provides quantitative coverage of four clinically relevant2,3 breakpoints – p.190, p.210, p.203 and p.230. Most other products offer only single breakpoint detection. To the patient, this means a higher level of accuracy by providing broader testing coverage, ensuring they are put on the correct treatment. 2. ABL1 mutation detection removes the need for an additional testing step. Upon finding a positive result, labs may reflex to ABL1 sequencing to determine point mutations that may impact treatment decisions. Precipio’s 2.0 assay will identify point mutation clusters associated with specific therapeutic indications, enabling a lab to bypass this additional step.3. Unparalleled workflow simplicity reduces labor time and cost. As with all HemeScreen assays, the reagents come in either pre-plated reagents, or in free-flow form, with all components pre-mixed. This creates unmatched simplicity for the lab staff by avoiding mixing and pipetting reagents, and all that is required is to pipette the extracted sample into the pre-plated wells. Furthermore, the new BCR-ABL 2.0 panel will come with an automated analysis software which will provide a direct analysis result that can be streamlined directly into the laboratory’s L...